Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTHQENC)

DTT Name Phosphodiesterase 1 (PDE1)
Synonyms PDE-I; Cam-PDE 1
Gene Name PDE1
DTT Type
Successful target
 [1]
BioChemical Class
Phosphoric diester hydrolase
UniProt ID
NOUNIPROTAC
TTD ID
T56367
Function Has a higher affinity for cgmp than for camp.

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vinpocetine DMVN2E6 Ischemic stroke 8B11.5Z Approved [1]
------------------------------------------------------------------------------------
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ITI-214 DM08TH3 Parkinson disease 8A00.0 Phase 1/2 [2]
------------------------------------------------------------------------------------
2 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
BIBW-22 DMXIH3Q Solid tumour/cancer 2A00-2F9Z Terminated [3]
ZAPRINAST DMGH3T5 N. A. N. A. Terminated [4]
------------------------------------------------------------------------------------
3 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
BUFROLIN DM61F5W Discovery agent N.A. Investigative [5]
isobutylmethylxanthine DM46F5X Discovery agent N.A. Investigative [5]
S,S-(2-Hydroxyethyl)Thiocysteine DMLPAD8 Discovery agent N.A. Investigative [6]
------------------------------------------------------------------------------------

References

1 Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology. 2009 Jun;73(6):1397-401.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells. Mol Pharmacol. 1996 Sep;50(3):482-92.
4 The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005 May 19;48(10):3449-62.
5 A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
6 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.